Osteoporosis is the most common age-related metabolic bone disorder, which is characterised by low bone mass and deterioration in bone architecture, with a propensity to fragility fractures. The best treatment for osteoporosis relies on stimulation of osteoblasts to form new bone and restore bone structure, however anabolic therapeutics are few and their use is timerestricted. Here we report that Syndecan-3 (SDC3) increases new bone formation through enhancement of WNT signalling. Young adult Sdc3 -/mice have a low bone volume phenotype associated with reduced bone formation, increased bone marrow adipose tissue (BMAT), increased bone fragility and a blunted anabolic bone formation response to mechanical loading. The premature osteoporosis-like phenotype of Sdc3 -/mice is primarily explained by delayed osteoblast maturation and impaired osteoblast function, with contributing increased osteoclast-mediated bone resorption. Mechanistically, SDC3 enhances canonical WNT signalling in osteoblasts through stabilisation of Frizzled 1, making SDC3 an attractive target for novel anabolic drug development.
INTRODUCTION
Osteoporosis is the most common age-related metabolic bone disorder affecting millions of people worldwide and predicted to rise as the population ages 1 . Osteoporosis is characterised by low bone mass and impaired bone micro-architecture, which predispose to fragility fractures, approximately 9 million annually 2 . Only a small number of anabolic treatments is available, use of which is time-limited and restricted to severe cases 3 . As osteogenic therapeutics are better than anti-resorptives, due to their ability to restore bone mass and architecture, there is a pressing need to gain a better understanding of anabolic pathways leading to bone formation so that novel management strategies can be developed.
One of the most important signalling pathways inducing osteoblastogenesis and bone
formation is WNT-dependent 4 . Mechanical loading of bone induces osteogenesis through the activation of the canonical (β-catenin-dependent) WNT-signalling, subsequent to repression of sclerostin, a WNT inhibitor expressed by mechanosensing osteocytes. 5 The canonical WNT-signalling pathway is activated by WNT ligands, which bind to the receptor complex comprised of frizzled (FZD) and the low density lipoprotein receptorrelated proteins 5/6 (LRP5/6) to indirectly inhibit phosphorylation of β-catenin, allow for its translocation into the nucleus and induction of β-catenin-response genes including AXIN2 4 .
WNT signalling intensity depends on the availability of FZD receptors, the level of which is regulated by ubiquitin-mediated degradation involving E3 ubiquitin ligases (ZNRF3 or RNF43), dependent on, or independent of leucine-rich repeat containing G protein-coupled receptors (LGRs) 6, 7 . In the presence of extracellular R-spondins (RSPOs), which bind to
LGRs, the RSPO-LGR complex interacts with ZNRF3/RNF43 and prevents the latter from tagging FZD for degradation. Thus, the resulting high level of FZD allows for strong WNTinduced signalling 6 . Inactivating mutations of RSPO2, which interfere with RSPO2-LGR or -RNF43 interaction, inhibit WNT signalling and induce limb abnormalities in humans 7 and mice 8 . However, as deletion of LGRs does not recapitulate this phenotype, another, LGRindependent, mechanism of regulation of FZD level has been proposed 7 and evidence presented indicating that it may involve heparan sulphate proteoglycans (HSPGs), including syndecans (SDCs) 6, 9 . Interestingly, a gene expression study of human bone subject to mechanical loading revealed that some of the induced pathways are mediated by SDCs 10 .
SDCs are a family of four type 1 transmembrane HSPG receptors, which play a role in cell adhesion, signalling, and are co-receptors for growth factors and their receptors. SDCs contain three domains: an N-terminal ectodomain, a transmembrane-and a C-terminal cytoplasmic domain. The ectodomain, which can be shed, mediates cell-cell and cell-matrix interaction through the attached glycosaminoglycan (GAG) chains including heparan sulfate (HS) in case of SDC2 and SDC4, and both HS and chondroitin sulfate (CS) in case of SDC1 and SDC3. The transmembrane domain allows for dimerization, whereas the cytoplasmic domain (composed of conserved regions C1 and C2 flanking a variable region [V]) interacts with kinases, the cytoskeleton and C1 mediates endocytosis 11,12 . GAGs, abundant in the extracellular matrix (ECM), are known to enhance bone regeneration and osteoblastogenesis by binding of the WNT inhibitor, sclerostin. However, with ageing the amount of GAGs, and in particular CS decreases in human cortical mineralised bone matrix, which has a detrimental effect on bone toughness and likely contributes to the agerelated deterioration of bone quality 13 . Previous research 14 has shown that HS GAGs are important in osteoblast differentiation and activity, and SDCs with attached GAGs, can modulate WNT signalling 15, 16 , however SDC-WNT crosstalk in bone has not been clearly deciphered 4, 17 and involvement of SDCs in bone physiology is poorly defined. SDC3 is expressed in the bone shafts of developing chick embryos 18 and plays a complex role in regulating chondrocyte proliferation 19, 20 , however its exact role in skeletogenesis or bone homeostasis is not fully understood.
Here we demonstrate that deletion of Sdc3 leads to a premature low bone volume phenotype associated with increased bone fragility and increased bone marrow adipose tissue (BMAT) in young adult mice. The underlying mechanism involves impaired bone formation and attenuated anabolic bone response to mechanical loading, explained by impaired canonical WNT3a-mediated signalling and likely due to increased degradation of FZD1 receptor in osteoblast-lineage cells.
MATERIALS AND METHODS

Mice
Sdc3 -/mice were housed in a pathogen-free facility at the University of Liverpool, with free access to food and water, and in accordance with the Animals (Scientific Procedures) Act 1986 and the EU Directive 2010/63/EU, after the local ethical review and approval by Liverpool University's Animal Welfare and Ethical Review Body (AWERB). Sdc3 -/mice on C57Bl6 background 21 were donated by Dr Heikki Rauvala, University of Helsinki, Finland.
Sdc3 -/mice were generated from heterozygous and/or one generation homozygous breeding.
Control wild type (WT) mice were littermates or closely related, age-and sex-matched.
In vivo mechanical loading
The right tibiae of 10-week-old male Sdc3 -/-(n=8) and WT (n=7) mice were mechanically loaded to induce metaphyseal bone formation, as described 22 . Briefly, mice were anaesthetised using Isoflurane through the whole procedure. The right knee and ankle were placed in custom made cups in the ElectroForce® 3100 Test Instrument (Bose Corporation, MN, USA) and repetitive mechanical compression applied at a peak magnitude of 11N for 0.05sec. Baseline hold time of 2N was applied for 9.9sec to maintain the tibia in place in between peak load applications. Each loading episode consisted of 40 cycles and was applied 6 times over a period of 2 weeks. Mice received calcein (2mg/ml) 150µl intraperitoneal injections on days 8 and 12 (day 1 = first loading day). Mice were culled 3 days after the final loading episode and tibiae collected.
µCT analysis
The skin was removed, and hind limbs and spines were fixed overnight in 4% formalinbuffered saline and stored in 70% ethanol. µCT analysis was performed using a Skyscan 1272 system. For assessment of bone morphometry, tibias, femurs and the lumbar spine were dissected free of most soft tissue and scanned at a resolution of 4.5 µm (60 kV, 150 µA, rotation step size 0.3°, using a 0.5 mm aluminium filter). The reconstruction was performed using the Skyscan NRecon package. Trabecular parameters were measured using Skyscan CTAn software in a stack of 200 slices immediately proximal, or distal to the growth plate in femurs, or tibias respectively, as described previously 23 . Tibial and femoral cortical parameters were measured using Skyscan CTAn software in a stack of 100 slices immediately proximal to the tibio-fibular junction and distal to the trochanter respectively. Trabecular bone was separated from cortical bone using a CTAn macro, and the same macro then performed measurement of the cortical and trabecular parameters according to ASBMR guidelines 24 . For tibial length quantification, the full length of mineralised tibial diaphysis at P2, and the distance between proximal and distal growth plate during skeletal maturation was measured on µCT longitudinal scans of 9 µm resolution using the Data Viewer.
For measurement of the whole bone volume of the tibial bone shaft of 2 day-old and 2-week old mice, tibias were scanned at a resolution of 9µm, and reconstructed as detailed above.
Using a macro in CTAn, the bone was separated from soft tissues using a fixed threshold and bone volume measured between the proximal and distal growth plates.
Bone histomorphometry and histology
Bone samples were processed and stained for histology as previously described 25 . Briefly, mice received intraperitoneal calcein injections (2mg/ml, 150µl) 5 days and 2 days before culling. The skin was removed, hind limbs were fixed for 24h in 4% formalin, and stored in 70% ethanol. The samples were embedded in methyl methacrylate (MMA) and 5µm sections were cut using a tungsten steel knife on a Leica motorised rotary microtome. Sections were stained for TRAcP to visualise osteoclasts and counterstained with Aniline Blue. For analysis of calcein double labelling, sections were counterstained with Calcein Blue and histomorphometry performed as described previously 25 For analysis of the growth plate, mouse knees were decalcified in formical overnight, embedded in wax and 5 µm sections cut on a Leica rotary microtome. Sections were stained for haematoxylin as well as Safranin O/fast Green, imaged using the Zeiss Axio Scan.Z1 using a x10 lens, and growth plate width measured using Zeiss Zen software.
Three-point bending test
Flexural strength of the femurs from 3-month old Sdc3 -/and WT mice was assessed by dynamic three-point bending test on freshly dissected, unfixed bones using the ZWICKmechanical testing machine (ZWICK, Switzerland), using a span of 8mm between the support points and a crosshead speed of 1 mm/min.
Osteoclast culture
Bone marrow was obtained from 2-3-month-old mice and cultured with 100 ng/ml of M-CSF (Prospec Bio) in αMEM (Gibco Invitrogen) supplemented with 10% FCS for three days.
Next the adherent M-CSF dependent macrophages were harvested and plated in 96-well plates at 10 4 cells/well in αMEM supplemented with 10% FCS, 25 ng/ml M-CSF and varying amounts of RANKL (R&D Systems), according to standard methods as previously described 26 . After 5-6 days of culture, the cells were fixed using 4% paraformaldehyde in PBS, washed and stained for TRAcP. Numbers of osteoclasts were counted after TRAcP staining by an observer blinded to the genotype. Resorption assays were performed using the same method, but by plating the cells on dentine slices placed within 96-well plates. After six days, the plates were fixed and stained for TRAcP, and number of osteoclasts per dentine slice counted. Next the cell layer was polished off the dentine slices, and the entire slices imaged using an Olympus reflected light microscope (5x lens) fitted with a Zeiss axiocam camera (isotropic pixel size 1.2µm). Individual fields (8-9 per slice) were stitched together using Microsoft ICE, and the pit area measured using ImageJ.
Osteoblast culture
Bone marrow was obtained from the long bones of 2-3-month-old mice by removing the ends of the bones to expose the bone marrow cavity, followed by centrifugation at 300g for 3 min.
Bone marrow mesenchymal stromal cells (BMSCs) were cultured in DMEM (Gibco Invitrogen) supplemented with 10% FCS and antibiotics (non-osteogenic culture conditions).
Osteoblasts were differentiated from BMSCs by culturing in osteogenic medium, DMEM supplemented with 10% FCS, 1% P/S, 2mM β-glycerophosphate (Sigma-Aldrich) and 50µg/ml 2-Phospho-L-ascorbic acid trisodium salt (Sigma-Aldrich). After removal of the bone marrow, the remaining femoral and tibial diaphysis were cut into small pieces followed by collagenase digestion for 30 min. The bone chips were washed in PBS and cultured in αMEM supplemented with 10% FCS in 25 cm 2 tissue culture flasks until semi confluent layers of osteoblasts (bone chip osteoblasts, BC) had grown out of the bone chips. The cultures were washed with PBS and the osteoblasts harvested using trypsin.
Calvarial osteoblasts were isolated from the calvaria of 2-3 day-old pups by collagenase digestion as described in detail previously 27 and cultured in αMEM supplemented with 10% FCS and antibiotics.
For alkaline phosphatase assays, BC osteoblasts were plated at 15x10 3 cells/well in 96-well plates and cultured in 150 µl αMEM with 10% FCS for 24 hours. Alamar Blue (15 µl/well) was added to the culture and culture continued for 2 more hours. Cell viability was measured by analysing the Alamar Blue signal using a fluorescence plate reader (BMG FLUO Star Optima, excitation 560 nm, emission 590 nm). Next the cells were fixed for 10 min at 4°C using 4% paraformaldehyde in PBS, washed and stored dry at -20 °C. Alkaline phosphatase was measured using the conversion of para-nitrophenyl-phosphate by measuring absorption at 405 nm at 1 min intervals for 30 min. Alkaline phosphatase measurements were corrected for cell number by dividing by the Alamar Blue signal.
For mineralisation assays osteoblasts, either derived from bone chips or calvaria, were cultured for 26 days in mineralising-medium containing DMEM (Gibco Invitrogen) supplemented with 10% FCS, 1% P/S, 2mM β-glycerophosphate (Sigma-Aldrich) and 50µg/ml 2-Phospho-L-ascorbic acid trisodium salt (Sigma-Aldrich). Half medium changes were made every other day during induction period and mineralising-medium was made up fresh every time. Calcium deposition in the mineralisation assay, at day 26, was measured using Alizarin Red staining. Osteoblasts were fixed in 70% ice cold Ethanol for 1h on ice and washed in dH2O. Cells were then incubated in Alizarin Red S (Sigma-Aldrich) solution for 20 minutes at room temperature on a rocking table, washed in dH2O overnight and then air dried. Quantification was performed by dissolving the alizarin Red in 10% (w/v) cetylpyridinium chloride in 10mM sodium phosphate, and measuring absorbance at 562 nm as previously described 28 . For mineralisation assays of BMSC, cells were grown to confluence in 12 well plates in DMEM supplemented with 10% FCS and antibiotics. Medium was changed to osteogenic medium and culture continued for 10 days with half medium changes every other day. Cultures were fixed and stained for Alizarin Red S as described above.
Adipo-osteogenic culture of bone marrow stromal cells
BMSCs were isolated from mouse long bones as described above, plated at 2x10 6 cells per cm 2 in αMEM supplemented with 15% FCS and grown until confluent (approximately 10 days) with twice weekly medium changes. After reaching confluence the medium was replaced with co-differentiation adipogenic and osteogenic medium, αMEM supplemented with 10% FCS, 2mM β-glycerophosphate, 50µg/ml 2-Phospho-L-ascorbic acid trisodium salt and 100 nM dexamethasone (Sigma-Aldrich), adapted from Ghali et al 29 . Culture was continued with 3-weekly changes of medium for 12 more days, plates fixed, and adipocytes stained with Oil-red-O. After staining, the plates were imaged using a Nikon Diaphot inverted microscope fitted with a Touptec camera, using a 10x lens, and number of adipocytes per image field counted, counting at least 3 fields for every mouse cell donor.
Cell proliferation assay
Anti-Ki67 (Abcam) was used to determine cell proliferation. BC-differentiated osteoblasts from Sdc3 -/-(n=6) and WT (n=7) mice were plated on glass cover slips (6 per mouse) in 24well plates, cultured for 48h, fixed in 100% Methanol for 5 minutes, permeabilized with 0.1%
Triton-X-100 for 5 minutes and then blocked with 10% FCS in PBS for 1h. The cells were then incubated with Anti-Ki67 antibody at 1:250 dilution overnight at 4ºC. Fluorescent Alexa-fluor-488 conjugated antibody (Life Technologies) at 2µg/ml was used for detection.
Nuclei were stained with DAPI. The coverslips were imaged using a Zeiss Axio Scan.Z1 using a x20 lens, and Ki-67 positive and negative nuclei quantified using a macro in ImageJ. Table 1 ). Hmbs was used as a house keeping gene, and expression was calculated as relative expression to this house keeping gene using the delta-CT method. For experiments on the effects of WNT3a, cells were cultured as described until near-confluence and after overnight serum starvation (where 10% FCS was replaced by 2% TCM), recombinant mouse WNT3a protein (Abcam) 50ng/ml was added and cells cultured for 8 hours before lysis in Trizol.
Western Blotting
Cells were cultured as described above. After cell lysis using standard RIPA buffer, proteins were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and electroblotted onto nitrocellulose membranes (Bio-Rad). Membranes were blocked with blocking buffer (LI-COR) and probed with primary antibodies to FZD1 (1:750, R&D), βcatenin and GAPDH (1:1000, Cell Signalling). After washing with TBST, membranes were incubated with appropriate LI-COR infrared-labelled secondary antibodies, visualised using the Odyssey CLx imaging system (LI-COR) and analysed using Image Studio lite (LI-COR, 5.2).
Statistical analysis
All experiments were performed with a minimum of 3 biological replicates, unless indicated otherwise. Statistical analysis was performed in SPSS using a (two-tailed) Student's t test, unless indicated otherwise and a p < 0.05 was considered statistically significant.
RESULTS
Syndecan-3 deletion results in a low bone volume phenotype in adult mice
Morphometric µCT analysis of proximal tibiae of 3 month-old male Sdc3 -/mice revealed a decrease in bone volume (BV/TV), trabecular thickness (Tb.Th) and trabecular number (Tb.N) of 34% (p<0.001), 13% (p<0.001) and 24% (p<0.001) respectively and an increase in trabecular separation (Tb.Sp), trabecular pattern factor (Tb.Pf, indicating reduced connectivity), and structure model index (SMI, indicating a more rod-like rather than platelike structure), of 10% (p<0.05), 50% (p<0.001) and 20% (p<0.001) respectively compared to WT mice (Fig. 1a, b and Supplementary Table 2a ). Morphometry of distal femora showed similar results in keeping with a low trabecular bone volume phenotype in young adult Sdc3 -/mice ( Fig. 1b and Supplementary Table 2a ).
Cortical thickness (C.Th), periosteal perimeter (P.Pm) and polar mean moment of inertia (MMI) were decreased by 8% (p<0.01), 9% (p<0.05) and 34% (p<0.05) respectively in the tibiae of 3-month old male Sdc3 -/mice vs WT ( Fig. 1c and Supplementary Table 2b ).
Morphometry of femoral cortex showed a decrease in C.Th, P.Pm, endosteal perimeter (E.Pm) and MMI of 11% (p<0.001), 6% (p<0.01), 12% (p<0.001) and 21% (p<0.01) respectively in Sdc3 -/vs WT ( Supplementary Table 2b ). As expected from the results of the µCT analysis, the three-point bending test applied to femurs revealed a 27% (p<0.001) and 40% (p<0.001) reduction in maximum force and work to fracture respectively in the Sdc3 -/vs WT mice, as well as a 20% reduction in stiffness (p<0.001) ( Fig. 1d) , indicative of bone fragility in Sdc3 -/mice. Spinal morphometry showed a decrease in BV/TV and Tb.Th in Sdc3 -/vs WT as well ( Fig. 1e) . Thus, Sdc3 deletion induces a low bone volume phenotype in both the trabecular and cortical compartments in adult mice, which is associated with bone fragility.
Syndecan-3 differentially regulates prenatal and postnatal bone development
To ascertain whether the low bone volume phenotype of adult Sdc3 -/mice was due to a developmental defect, we measured the total bone volume and length of tibiae just after birth and during skeletal maturation. Surprisingly, tibiae from 2-day old Sdc3 -/pups had an approximately 40% higher bone volume vs WT (p<0.001), however by 2 weeks of age the Sdc3 -/mice tibia bone volume was approximately 20% lower than that of the WT (p<0.01; Fig. 2a ). There was no difference in trabecular BV/TV between the genotypes at 6 weeks, however as of 8 weeks of age the BV/TV was significantly lower in Sdc3 -/vs WT mice (p<0.001; Fig. 2b ). This differential bone volume variation was mirrored by changes in the tibial longitudinal growth. Thus at 2 days of age the tibiae of Sdc3 -/mice were 0.8 mm longer than those of WT (p<0.001; Fig. 2c ), however this difference was reversed already by 2 weeks, at which stage the Sdc3 -/tibiae were shorter by 0.9 mm vs WT (p<0.001) and remained shorter throughout (Fig.2c) . Taken together this data indicate that SDC3 has a differential effect on pre-and post-natal longitudinal bone development and growth.
As SDC3 is known to attenuate BMP2-mediated limb chondrogenesis 30 , we measured the growth plate width in the proximal tibia of 3-month old mice, and found it thinner in Sdc3 -/vs WT mice, p<0.001 ( Fig. 2d and f) . Furthermore, the hypertrophic zone width was reduced, p<0.05 ( Fig. 2e and g) , and disorganised growth plate morphology was evident, with poorly stacked chondrocytes in irregular columns within the proliferating zone and a virtual absence of primary spongiosa ( Fig.2d and e ), which in part may explain the decreased long bone growth in young and adult Sdc3 -/mice. Table 3 ).
Low bone volume phenotype in adult Sdc3
The rate of osteoclast formation induced by MCSF and RANKL in vitro was significantly lower in osteoclastogenesis cultures derived from Sdc3 -/vs WT 3-month old mice ( Fig.3c   and d) , confirming the histology findings ( Fig.3a and b) , and indicating that the decreased osteoclast formation is due to a cell autonomous defect in response to RANKL. Interestingly, cultures of osteoclasts on dentine slices did not show a difference in resorption area between Sdc3 -/and WT (Fig.3e) , however due to there being fewer Sdc3 -/osteoclasts vs WT formed per dentine slice (80.6±18.4 vs 141.2±98.5 respectively, p<0.05), the resorption area per osteoclast was over twofold higher in Sdc3 -/vs WT cultures, p<0.01 (Fig.3f) . These findings suggest that SDC3 promotes osteoclast differentiation but decreases mature osteoclast resorptive activity.
To gain insight into the mechanistic role of SDC3 in osteoclastogenesis, we examined osteoclast marker gene expression during osteoclast differentiation in vitro. Only at the early, MCSF-dependent macrophage stage, did we find a significant decrease in the Tnfrsf11a encoding RANK in Sdc3 -/vs WT (Fig.3g) , which may explain lower sensitivity of Sdc3 -/macrophage-lineage cells to RANKL and consequently impaired osteoclastogenesis. The expression of the major transcription factor inducing osteoclastogenesis, Nfatc1, increased during osteoclast differentiation, as did the late osteoclast markers Dcstamp and Ctsk as expected, with no significant differences between genotypes. Interestingly Sdc3 expression significantly increased in osteoclasts vs MCSF-dependent macrophages, suggesting a role for SDC3 in mature osteoclasts (Fig.3g) . Given that during osteoclast formation RANK expression has been shown to be induced by the FZD-mediated non-canonical WNT signalling pathway ROR/JNK/c-JUN 31 and FZD7 is highly expressed 32 , whereas in Xenopus FZD7 associates with SDC4 and RSPO3 in the non-canonical WNT/PCP pathway during endocytosis 16 , we assessed Fzd7 expression during osteoclastogenesis. Interestingly, again
Fzd7 expression was significantly lower in Sdc3 -/-MCSF-dependent macrophages, but not at the pre-osteoclast or osteoclast stage (Fig.3g ). As FZD7 is involved in both canonical and non-canonical WNT-signalling 16, 33, 34 and is likely induced by β-catenin itself through the TCF/LEF promoter binding site 35 , taken together our data suggest that SDC3 enhances early stages of osteoclast differentiation via WNT-signalling and plays a role in mature osteoclasts, however the exact mechanism of action of SDC3 in osteoclast lineage cells is currently unclear.
Low bone volume phenotype in adult Sdc3 -/mice is due to impaired osteoblast maturation and reduced bone formation
Dynamic histomorphometry of bone formation using calcein double-label quantification in 3 month-old Sdc3 -/mice revealed a decrease of 35% in BV/TV (p<0.001), 21% in the mineral apposition rate (MAR, p<0.01), 36% in the mineralising surface per bone surface (MS/BS (p<0.05) and 50% in the bone formation rate per bone surface (BFR/BS (p<0.001) vs WT ( Fig.4a and b, 
and Supplementary Table 3) in keeping with low bone formation rate in
Sdc3 -/mice. Functional assays confirmed an over 2-and 6-fold reduction in mineralisation in Sdc3 -/vs WT cultures of osteoblasts differentiated from BMSCs and from BCs respectively ( Fig.4c and d) . Sdc3 -/osteoblasts grown out of calvariae also showed significantly reduced mineralisation capacity vs WT (Fig.4c and d) . Unsurprisingly, alkaline phosphatase activity was reduced by 70% in Sdc3 -/vs WT osteoblasts differentiated from BCs in vitro (p<0.001; Fig.4e) , indicating that the low bone formation rate seen in Sdc3 -/mice on histomorphometry is due to impaired osteoblast function. As the proliferation rate of osteoblasts assessed by the Ki67 assay was higher in Sdc3 -/compared to WT cultures (9.1±1.7 vs 7.0±1.1, p<0.05), taken together these data suggest that SDC3 is important for timely maturation of proliferating osteoblasts and normal bone formation and mineralisation.
The functional impairment of Sdc3 -/osteoblasts was corroborated by the finding of downregulated osteoblastic differentiation and activity genes: Runx2 by 75% (p<0.01), Alpl (encoding alkaline phosphatase) by 70% (p<0.01), Bglap (encoding osteocalcin) by 70% (p<0.05) and Col1a1 by 55% (p<0.01) vs WT (Fig.4f) . In addition, we quantified Sdc1, Sdc2
and Sdc4 expression in osteoblasts, to assess whether other syndecans might be increased in an effort to compensate for lack of Sdc3, however found no differences between Sdc3 -/and WT osteoblasts (Supplementary Fig.1) .
As bone responds with new bone formation to mechanical loading, we assessed this anabolic response in vivo. As expected, in WT mice mechanical loading of the tibia induced an increase in mineralising surface (MS/BS) and in bone formation rate (BFR/BS) of 41% (p<0.001) and 48% (p<0.05) respectively in the loaded vs non-loaded tibia. However, in Sdc3 -/mice the anabolic response to mechanical loading was blunted: the increase in MS/BS and BFR/BS in the loaded vs non-loaded tibia was only 12% and 21% respectively ( Fig.4h and Table 1) , and not statistically significant.
Bone marrow adiposity is increased in Sdc3 -/mice
As Sdc3 deletion leads to a bone phenotype mimicking premature osteoporosis, which in humans is typically associated with increased bone marrow adipose tissue (BMAT), we quantified BMAT, seen as empty spaces in the bone marrow on the Goldner's Trichrome stain, after the void areas had been confirmed to contain adipocytes on perilipin staining ( Fig.5a ). Histomorphometry analysis of tibial and femoral bones from 3-month old mice revealed a 60-fold increase in bone marrow adipocyte number and area in Sdc3 -/compared to WT (p<0.001, Fig.5b and c) . In vitro, a two-fold increase in adipocyte formation was observed in Sdc3 -/vs WT BMSCs cultured in adipo-osteoblastogenesis conditions (Fig.5d-f) and adipocytes formed 1-2 days earlier in Sdc3 -/than WT cultures. Thus, deletion of Sdc3 leads to a premature osteoporosis-like phenotype characterised by not only low bone volume and fragility, but also increased BMAT, possibly due to a preferential switch from osteoblastogenesis to adipogenesis at a progenitor level.
Syndecan-3 enhances canonical WNT signalling pathway in osteoblasts
Given that a common signalling pathway enhancing osteoblastogenesis, mediating anabolic response to mechanical loading and in cartilage critical for normal growth plate development is WNT-mediated 4,36 , we hypothesised that SDC3 enhances WNT signalling.
To assess the effect of Sdc3 deletion on canonical WNT-signalling, osteoblasts were stimulated with WNT3a, which has been shown to enhance osteoblastogenesis 37, 38 , and the main β-catenin target gene Axin2 quantified by qPCR. In Sdc3 -/osteoblast cultures there was a significant reduction in Axin2 expression compared to WT controls regardless of whether the osteoblasts were grown out of BCs or differentiated from BMSCs, which was mostly apparent after stimulation with WNT3a ( Fig.6a ) and in keeping with decreased canonical WNT-signalling in the absence of SDC3.
Thus, we further assessed the main canonical WNT-signalling pathway components at mRNA level and found no difference in expression of Lrp5 or 6, Lgr4-6, Znrf3 and Rnf43, in Sdc3 -/vs WT osteoblasts (data not shown). From the Fzds involved in canonical WNT signalling (i.e. Fzd1, 5, 7 and 9), Fzd1 expression in osteoblasts was highest (Fig.6b ) in keeping with previous reports 39 . As FZD1 enhances osteoblast-mediated mineralisation 40 , we quantified FZD1 and β-catenin at protein level and found both reduced by 72% and 73% respectively in Sdc3 -/vs WT (p<0.001) in BMSC-derived osteoblasts grown in osteogenic conditions ( Fig.6c and d) . In osteoblasts derived from bone-chips, FZD1 and β-catenin were reduced by 52% (p<0.01) and 34% (p<0.01) respectively in Sdc3 -/vs WT (Fig.6c and d) . In contrast, β-catenin levels were considerably higher in BMSCs cultured in non-osteogenic conditions, and there was no difference in either FZD1 or β-catenin levels between Sdc3 -/and WT in these cells. Taken together, these data suggest that in osteoblasts SDC3 enhances the canonical WNT-signalling pathway by stabilising FZD1.
DISCUSSION
Here we have identified a novel anabolic role for SDC3 in bone. Deletion of Sdc3 leads to low bone volume, increased bone fragility and increased bone marrow fat in young adult mice, a premature osteoporosis-like phenotype.
Interestingly, SDC3 differentially affects pre-and post-natal long bone growth. Sdc3 deletion resulted in increased long bone elongation in utero, in keeping with the known restrictive role of SDC3 at two stages of skeletal development. Firstly, during the condensation stage of early pre-cartilaginous skeletogenesis SDC3 restricts the size of mesenchymal cell aggregates and promotes the differentiation step 18, 41, 42 . Secondly, during limb elongation SDC3 is thought to set boundaries at the metaphyseal and epiphyseal perichondrium and periosteum 41, 43 . Thus, deletion of Sdc3 would allow for a relative expansion of the cartilaginous skeleton, explaining the longer bones seen early postnatally in Sdc3 -/mice. Moreover, it has been previously shown that SDC3 regulates proliferation and maturation of chondrocytes in the growth plate during embryonic long bone development 20, 44, 45 and restricts chondrogenic differentiation in vitro 30 . Our data indicate that SDC3's regulatory role extends into adulthood as SDC3 deletion leads at 3 months of age to a thin growth plate with disorganised columns of chondrocytes within the proliferating zone, which is associated with mild, but significant long bone growth stunting compared to the reverse seen in utero. This growth plate abnormality may be due to defective chondrogenesis at stem cell level in the growth plate resting zone 46, 47 , and/or at the proliferation and differentiation stages of chondrocytes 19, 20 , in which extracellular matrix, with which transmembrane HSPGs interact, is thought to play a role. Further investigations are in progress to assess the exact role of SDC3 in the regulation of chondrocytes within the growth plate and in longitudinal bone growth.
Significantly, the relatively large total long bone volume of Sdc3 -/pups is not only not maintained into adulthood but reversed already at 2 weeks of age, whereas the trabecular bone volume (BV/TV) becomes significantly lower at 2 months and remains low. Whilst the shortening of the long bones in Sdc3 -/adult mice reflects a thinner and morphologically abnormal growth plate, the low bone volume phenotype is unexpected. However, a similar long-bone phenotype has been reported in young adult mice deficient in the heparin-binding growth molecule (HB-GAM, also known as osteoblast stimulating factor 1 [OSF1] and pleiotrophin), expressed at the growth plate and around osteocytes in bone 48, 49 . Thus, our findings indicate that SDC3, like HB-GAM, mediates an osteogenic effect in response to mechanical loading, given that SDC3 likely serves as receptor for HB-GAM on osteoblasts, as has been previously shown in neurons 50 .
Although osteoclastogenesis is decreased in Sdc3 -/mice (like in HB-GAM -/-), the relative scarcity of osteoclasts is likely offset by increased osteoclast-mediated bone resorption, which may be contributory to the low bone volume phenotype. The latter finding contrasts with the lack of effect of HB-GAM on osteoclastic bone resorption 48 . Our observation of a gradual increase in SDC3 expression during normal osteoclast differentiation suggests its importance for osteoclast maturation and/or function. Indeed, reduced expression of Tnfrsf11a encoding RANK and Fzd7 in MCSF-dependent Sdc3 -/macrophages, is reflected by reduced sensitivity to RANKL and suggests that SDC3 may enhance pathways targeting 31 . On the other hand, it is tempting to speculate that SDC3 may associate with FZD7 during cell polarisation, not unlike SDC4 during the planar cell polarity (PCP) process in Xenopus, which also leads to activation of JNK 16 . Furthermore, in human breast epithelial cells FZD7 is induced by NOTCH signalling 52 , which is known to crosstalk with SDC3 during myogenesis 53 , thus further research is currently ongoing exploring the SDC3-NOTCH crosstalk in bone. Our findings are not explained by the lack of the SDC3 ectodomain in the light of Kim's and colleagues recent report of a suppressive effect of SDC1-4 ectodomains on osteoclastogenesis and of SDC1, 2 and 4 (but not SDC3) ectodomains on osteoclast mediated bone resorption 54 .
The Sdc3 -/mouse low bone volume phenotype primarily reflects impaired osteoblastic bone formation, which is associated with increased bone marrow adiposity, suggesting either a preferential switch at the mesenchymal progenitor level from osteoblastogenesis to adipogenesis, or potential de-differentiation of osteoblasts towards adipocyte lineage. It is unlikely that systemic factors play a significant role in this aspect of the phenotype, as at a cellular level there is increased adipocyte formation seen in Sdc3 -/-BMSCs vs WT in vitro.
Indeed, the delay in Sdc3 -/osteoblast differentiation suggests a degree of immaturity of differentiated Sdc3 -/osteoblasts, which display impaired ability to not only form, but also fully mineralise newly formed bone. The blunted anabolic response of bone to mechanical loading in Sdc3 -/mice is not due to muscle dysfunction as deletion of Sdc3 in fact improves muscle homeostasis, regeneration and ageing, in both healthy and dystrophic mice 55 .
Moreover, Sdc3 -/mice are no different from WT in regard to endurance training performance 55 .
As the key pathways regulating skeletal development, inducing osteoblastogenesis 4 , inhibiting adipogenesis 56, 57 , and in cartilage inducing chondrocyte hypertrophy and regulating the morphology of the growth plate 36, 58 involve WNTs 4 , we focussed our investigations on the canonical WNT signalling. To our knowledge, involvement of SDC3 in WNT signalling has not been reported previously, although SDC1, 2 and 4 are co-receptors in WNT signalling 17 . Given the severity of the Sdc3 -/mouse bone phenotype, clearly SDC1, 2 and 4 are unable to compensate for lack of SDC3, indicating its specific role in the acquisition of bone volume and maintenance of normal bone homeostasis in adult mice.
We consistently found decreased expression of Axin2 in Sdc3 -/osteoblasts indicating impaired β-catenin signalling. Out of the Fzds classically involved in canonical WNT signalling, i.e. Fzd1, 5, 7 and 9 17 , we found Fzd1 expression in osteoblasts to be highest, as reported previosuly 39 . Given that FZD1 not only mediates osteoblast differentiation, but also bone mineralization 40 and that Sdc3 -/osteoblasts show impairment in both these functions, our findings of decreased FZD1 and β-catenin in Sdc3 -/osteoblasts may explain the Sdc3 -/phenotype. Furthermore, as Fzd1 RNA expression is not affected in Sdc3 -/osteoblasts, whereas at the protein level FZD1 is significantly decreased in committed Sdc3 -/osteoblasts, it is plausible that in the absence of SDC3, FZD1 undergoes rapid degradation, leading to decreased β-catenin signalling. Thus, we propose that in osteoblasts SDC3 enhances canonical WNT signalling and likely serves as co-receptor which stabilises FZD1, however, the exact molecular mechanism of this interaction remains to be explored. Interestingly, βcatenin levels were considerably higher in BMSCs grown under non-osteogenic conditions than in those cultured for 7 days in osteogenic conditions, findings similar to previously reported in a human pre-osteoblast SV-HFO cell line 39 . This may indicate that during osteoblast differentiation β-catenin levels, already low, are more critical and tightly controlled. Thus, any changes in FZD1 levels may have a relatively more pronounced effect on β-catenin signalling.
Although our findings indicate that SDC3 enhances canonical WNT signalling in the osteoblast lineage and both canonical and non-canonical WNT signalling in osteoclast lineage, other pathways remain to be investigated. These, in addition to the remaining WNT signalling pathways, include FGF, BMP and NOTCH, crosstalk of which orchestrates osteoblast differentiation 59 , given that SDCs have been shown to partake in all these pathways 60 . Importantly, interaction of SDC3 with HB-GAM has been shown to regulate osteoblast recruitment to sites of increased bone formation 49 and osteocytic HB-GAM expression is upregulated after mechanical loading 48 , thus investigation of this pathway in the Sdc3 -/mouse is ongoing.
In summary, SDC3 differentially affects pre-and postnatal bone development. SDC3 deletion leads to a low bone volume phenotype associated with high BMAT in young adult mice. The anabolic effect of SDC3 on bone is mediated through canonical WNT signalling in osteoblasts, likely through stabilisation of FZD1. Increased bone resorption, but decreased osteoclastogenesis in Sdc3 -/mouse, likely contributes to the low bone volume phenotype.
Thus, SDC3 is a novel therapeutic target for anabolic drug development for treatment of osteoporosis. Table 1 Anabolic response to mechanical loading analysed by histomorphometry
The right tibia of 10-week-old male WT and Sdc3 -/mice was mechanically loaded for 2 weeks as described, whereas the left tibia was not loaded. 
